DB Ashbourne Limited has been acquired by Ethypharm S.A
The shareholder of DB Ashbourne Limited (DBA) has sold the company to Ethypharm S.A. for an undisclosed consideration.
DBA currently markets and supplies a range of prescription-only medicines to the UK market, generating significant savings for the National Health Service (NHS) and has an exciting pipeline of products in development which will be supplemented with a wide range of additional products from the Ethypharm pipeline.
Ethypharm S.A. is a France-based company engaged in developing, manufacturing and licensing pharmaceutical products. Through the acquisition of DBA, Ethypharm continues to implement its strategy to develop a direct commercial presence in key territories in Europe to market central nervous system products, with a particular focus on pain and innovative treatments for addictions. DBA provides a pivotal platform to generate revenues in the important UK market and this acquisition, along with the deployment of its own commercial operations in France and Germany, will generate a large turnover.
“I am delighted to welcome the DBA team to the Ethypharm group. The acquisition of DBA is a significant step forward for us. The know-how and expertise of both companies are totally complementary and synergistic and DBA offers a great platform to launch products from our own pipeline,” declared Hugues Lecat, CEO of Ethypharm.
Oaklins Cavendish, based in the UK, advised the seller in this transaction.
Talk to the deal team
Lord Leigh of Hurley
Oaklins Cavendish
Related deals
Triscan has joined APA and Riverarch to accelerate growth in the European aftermarket
Triscan AS, a leading provider of OE-quality automotive spare parts for the professional aftermarket in Europe, has been acquired by APA Industries, LLC, a portfolio company of Riverarch Equity Partners.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreMEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn more